FDA: GSK's Zofran might increase risk of abnormal heart rhythm

09/15/2011 | Wall Street Journal, The

The FDA is investigating the safety of GlaxoSmithKline's Zofran, or ondansetron, because of concern that the treatment increases the risk of abnormal heart rhythm. Zofran prevents nausea and vomiting in patients undergoing chemotherapy, surgery and radiotherapy. The FDA said it will add recommendations to Zofran's label, including electrocardiogram monitoring in certain patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX